# A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions

> **NCT04138888** · PHASE1 · UNKNOWN · sponsor: **Pharmtechnology LLC** · enrollment: 32 (estimated)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use
- **DRUG:** Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use

## Key facts

- **NCT ID:** NCT04138888
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-31
- **Primary completion:** 2019-12-24
- **Final completion:** 2019-12-24
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2019-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138888, "A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting Conditions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04138888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*